Academic Highlights: Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 1 [CME]
J Clin Psychiatry 2008;69(3):487-494
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
Schizophrenia is a heterogeneous disorder in terms of course and treatment response. The field of pharmacogenetics, which seeks to reveal how genetic factors affect patients’ response to drugs, holds promise to help clinicians develop a better understanding of antipsychotic therapy,1 such as which patients might respond better or worse to specific agents or treatment in general or which patients might be at particular risk for serious adverse effects.
What do practicing psychiatrists need to know about using genetic tests?